Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?

Table 1

Anti-HIV broad neutralizing antibodies (bnAbs) in the past 10 years.

Viral epitope	Name	Year	Sample source	References
V1V2 glycan site	PG9, PG16	2009	Clade A-infected African	[27]
	CH01	2011	Chronically infected donor (CH0219)	[28]
	PGT145	2011	Chronically infected donor 84	[29]
	PGDM1400	2014	Chronically infected donor 84	[30]
V3 glycan site	PGT121, PGT125, PGT135	2011	HIV-1 infected donor (at least 3 years)	[29]
	10-1074	2011	Clade A-infected African donor (patient 10)	[31]
gp41 MPER	2F5	2009	PBMCs from patient SC44	[32]
	4E10	2009	PBMCs from patient SC44	[32]
	HK20	2010	Patients plasma that showed >80% neutralization	[33]
	M66.6	2011	PBMCs from patient SC44	[32]
	CAP206-CH12	2011	Subtype C HIV-1-infected South African donor CAP206	[34]
	10E8	2012	HIV-1-infected patient N152	[35]
	m43	2012	Phage-display	[36]
CD4 binding site	VRC01	2010	PBMCs from donor 45	[37]
	HJ16	2010	Patients plasma that showed >80% neutralization	[33]
	HGN194	2010	Patients plasma that showed >80% neutralization	[33]
	3BNC117	2011	RU01 B-cell clones from patient donor	[38]
	3BNC55	2011	RU01 B-cell clones from patient donor	[38]
	VRC-PG04	2011	Clade A1/D infected donor	[39]
	VRC-CH31	2011	Chronically infected donor (CH0219)	[28]
	NIH45	2011	RU12 B-cell clones from patient donor	[38]
	8ANC195	2011	RU12 B-cell clones from patient donor	[38]
	8ANC131	2011	HIV-1 infected donor RU8	[38]
	12A12	2011	RU16 B-cell clones from patient donor	[38]
	1B2530	2011	HIV-1 infected donor RU1	[38]
	3BC176	2012	HIV-1 infected patient 3B	[40]
	3BC315	2012	HIV-1 infected patient 3B	[40]
	CH103	2013	HIV-1 infected donor CH505	[41]
	N6	2016	HIV-1-infected patient Z258	[42]